The item you requested could not be found.
Funded Clinical Trial for Dogs with Hemangiosarcoma |
07/26/2010
Trial Summary This clinical trial will evaluate a novel anti-cancer agent in a limited number of dogs with hemangiosarcoma. All dogs will receive study drug; there is no placebo. Dogs will receive the study drug as daily, oral treatment with evaluations performed once weekly for the first 28 days, then once monthly. Blood samples are collected throughout the study to assess the metabolism and biological activity of this drug. During the course of the study, dogs will not be allowed any holistic therapy, chemotherapy, prednisone therapy, non-steroidal anti-inflammatory therapy or other investigational therapies unless approved by the investigator and the sponsor.
Trial Summary This clinical trial will evaluate a novel anti-cancer agent in a limited number of dogs with hemangiosarcoma. All dogs will receive study drug; there is no placebo. Dogs will receive the study drug as daily, oral treatment with evaluations performed once weekly for the first 28 days, then once monthly. Blood samples are collected throughout the study to assess the metabolism and biological activity of this drug. During the course of the study, dogs will not be allowed any holistic therapy, chemotherapy, prednisone therapy, non-steroidal anti-inflammatory therapy or other investigational therapies unless approved by the investigator and the sponsor.
Treatment of Splenic Hemangiosarcoma with Doxorubicin and Palladia |
04/06/2010
Palladia has been shown not only to have activity against mast cell tumors but also against other cancers through anti-angiogenenic pathways. Dogs in this clinical trial will receive standard of care chemotherapy (Doxorubicin) post splenectomy. Two weeks after completing the chemotherapy course the patient will start Palladia. Patients enrolled in this study will receive free Palladia and a reduced cost on follow-up visits.
Palladia has been shown not only to have activity against mast cell tumors but also against other cancers through anti-angiogenenic pathways. Dogs in this clinical trial will receive standard of care chemotherapy (Doxorubicin) post splenectomy. Two weeks after completing the chemotherapy course the patient will start Palladia. Patients enrolled in this study will receive free Palladia and a reduced cost on follow-up visits.
Clinical Trial For Canine Lymphoma is now closed to patients |
04/05/2010
Pet dogs that are enrolled in the study will receive a single dose of a novel, oral anti-cancer agent. Serial blood samples and lymph node aspirates will then be collected over a 24-hour period. Patients will return for evaluation 7 days after the single dose of therapy is administered. For participation, clients will receive $2000 towards oncology care.
Pet dogs that are enrolled in the study will receive a single dose of a novel, oral anti-cancer agent. Serial blood samples and lymph node aspirates will then be collected over a 24-hour period. Patients will return for evaluation 7 days after the single dose of therapy is administered. For participation, clients will receive $2000 towards oncology care.
2010 Office Hour Changes |
03/02/2010
At times it is necessary for us to make adjustments to our scheduled hours. When we need to make changes we will post them on our web site.
At times it is necessary for us to make adjustments to our scheduled hours. When we need to make changes we will post them on our web site.
Palladia, the new drug from Pfizer. |
07/22/2009
There has been much buzz and excitement surrounding FDA approval of Palladia (Pfizer), which is new drug licensed for treatment of mast cell tumors in dogs. Palladia is in the family of drugs called tyrosine kinase inhibitors which have been used in the treatment of cancer in humans for many years. Not only does Palladia provide veterinarians with a novel way to treat some of the more difficult mast cell tumors, it represents a commitment from drug companies like Pfizer to developing therapies specific for our veterinary cancer patients. Palladia is currently available only through veterinary oncologists and other selected specialists.
There has been much buzz and excitement surrounding FDA approval of Palladia (Pfizer), which is new drug licensed for treatment of mast cell tumors in dogs. Palladia is in the family of drugs called tyrosine kinase inhibitors which have been used in the treatment of cancer in humans for many years. Not only does Palladia provide veterinarians with a novel way to treat some of the more difficult mast cell tumors, it represents a commitment from drug companies like Pfizer to developing therapies specific for our veterinary cancer patients. Palladia is currently available only through veterinary oncologists and other selected specialists.
What You Need to Know About Palladia (toceranib phosphate) |
06/22/2009
Pfizer recently received FDA approval for a novel drug, Palladia that is indicated for the treatment of mast cell tumors in dogs.
Pfizer recently received FDA approval for a novel drug, Palladia that is indicated for the treatment of mast cell tumors in dogs.
N.E.V.O.G. is now seeing patients in Newington, NH and Woburn, MA (05/05/09) |
04/26/2009
The New England Veterinary Oncology Group LLP (NEVOG) the only private, full service, veterinary oncology care center in New England based in Waltham MA, is now seeing patients in New Hampshire at the Veterinary Emergency, Critical Care and Cancer Center of NH in Newington and Massachusetts Veterinary Referral Hospital in Woburn, MA. Drs. Kim Cronin, Jeff Philibert, Erin Romansik and Sheri Siegel bring to the Newington and Woburn offices the same high quality and compassionate care for which NEVOG is known.
The New England Veterinary Oncology Group LLP (NEVOG) the only private, full service, veterinary oncology care center in New England based in Waltham MA, is now seeing patients in New Hampshire at the Veterinary Emergency, Critical Care and Cancer Center of NH in Newington and Massachusetts Veterinary Referral Hospital in Woburn, MA. Drs. Kim Cronin, Jeff Philibert, Erin Romansik and Sheri Siegel bring to the Newington and Woburn offices the same high quality and compassionate care for which NEVOG is known.
Emergency on call for active patients |
08/21/2008
NEVOG is pleased to announce that we are now offering an on-call after hours emergency service. The goal of this service is to help make recommendations in emergency situations. A NEVOG clinician will be available by phone to offer advice and if needed, direct you to the appropriate emergency facility. We will also be able to consult with an emergency clinician if it is recommended that your pet be seen.
NEVOG is pleased to announce that we are now offering an on-call after hours emergency service. The goal of this service is to help make recommendations in emergency situations. A NEVOG clinician will be available by phone to offer advice and if needed, direct you to the appropriate emergency facility. We will also be able to consult with an emergency clinician if it is recommended that your pet be seen.
Pet Friendly Hotels |
11/23/2007
We are often asked if there are pet friendly hotels in the area. While we do know of some hotels that are designated as pet friendly our list is not 100% comprehensive.
We are often asked if there are pet friendly hotels in the area. While we do know of some hotels that are designated as pet friendly our list is not 100% comprehensive.
Dr. Kim L. Cronin